Syndrome des antiphospholipides « séronégatif » : mythe ou réalité ?

Salle, V.

doi:10.1016/j.revmed.2020.02.005

Cited by 4 publications

(2 citation statements)

References 136 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with SN-APS are at risk for recurrent thrombotic and pregnancy complications; long-term prophylactic treatment is therefore required [27]. Due to this reason, it has been currently proving increasingly beneficial to revise the original laboratory criteria of APS [16] and to include specifications of other non-criteria antibodies summarized in Table 2 [99]. The introduction of additional aPLs into routine laboratory practice will certainly represent a useful tool for more precise and accelerated APS diagnostics [54,100,101].…”

Section: Conclusion Seronegative Apsmentioning

confidence: 99%

Current Promising Biomarkers and Methods in the Diagnostics of Antiphospholipid Syndrome: A Review

et al. 2021

View full text Add to dashboard Cite

Antiphospholipid syndrome (APS) is a hypercoagulation condition associated with the incidence of heterogenic antiphospholipid antibodies (aPLs), which non-specifically affect hemostasis processes. APS is clinically manifested by recurrent arterial and venous thromboses and reproduction losses. The aPL antibodies, which may induce clinical manifestations of APS, include criteria antibodies anti-cardiolipin, anti-β2-glycoprotein-I, and lupus anticoagulant, but also non-criteria antibodies, for example anti-β2-glycoprotein-I domain I, anti-phosphatidylserine/prothrombin, anti-annexin V, and many others. APS occurs mostly in patients of younger and middle age, most frequently in females. Laboratory diagnostics of APS are quite difficult, as they include a wide spectrum of examining methods, which are based on various principles of detection and are performed using various laboratory techniques. The objective of the review is to describe the current state of potentially examined biomarkers and methods in APS diagnostics. The aforementioned biomarkers are lupus anticoagulant, anti-β2-glycoprotein-I, anti-cardiolipin, anti-β2-glycoprotein-I domain I, anti-phosphatidylserine/prothrombin, anti-β2-glycoprotein-I IgA, anti-cardiolipin IgA, anti-annexin V and II, anti-prothrombin, anti-cardiolipin/vimentin, anti-protein S/protein C, and antibodies against phospholipid antigens for whose diagnostics we may use some of the methods established for a long time and some of the modern methods—the coagulation method for the determination of lupus anticoagulant (LA), enzyme-linked imunosorbent assay (ELISA), chemiluminescence analysis (CLIA), multiplex fluorescence flow immunoassay (MFFIA), fluorescence enzyme immunoassay (EliA), line immunoassay (LIA), multiline dot assay (MLDA), and thin-layer chromatography (TLC). Conclusion: Antibodies against phosphatidylethanolamine, phosphatidic acid, phosphatidylserine, phosphatidylinositol, cardiolipin/vimentin complex, and annexin V are currently the most studied new markers. However, these assays have not been standardized until now, both from the laboratory and clinical point of view. In this review we summarize the evidence of the most studied aPL markers and their potential clinical significance in seronegative APS (SN-APS).

show abstract

Section: Conclusion Seronegative Apsmentioning

confidence: 99%

Current Promising Biomarkers and Methods in the Diagnostics of Antiphospholipid Syndrome: A Review

et al. 2021

View full text Add to dashboard Cite

show abstract

“…To describe these types of patients, Hughes and Khamashta defined the concept of "seronegative APS" and a growing interest in the development of new biomarkers that improve the diagnostic accuracy of APS has emerged (30). New aPL associated with APS clinical manifestations but not included in the current classification criteria have been described and are called extra-criteria aPL (31). Among them, aB2GPI of IgA isotype, IgG and IgM antiphosphatidylserine/prothrombin (aPS/PT) antibodies, and IgG anti-domain I of B2GPI antibodies stand out for their strong association with APS clinical characteristics and for the existence of well-standardized diagnostic tests (32)(33)(34).…”

Section: Introductionmentioning

confidence: 99%

Presence of Extra-Criteria Antiphospholipid Antibodies Is an Independent Risk Factor for Ischemic Stroke

Naranjo

Ostos

Gil‐Etayo

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Background: Ischemic stroke is the most common and severe arterial thrombotic event in Antiphospholipid syndrome (APS). APS is an autoimmune disease characterized by the presence of thrombosis and antiphospholipid antibodies (aPL), which provide a pro-coagulant state. The aPL included in the classification criteria are lupus anticoagulant, anti-cardiolipin (aCL) and anti-β2-glycoprotein-I antibodies (aB2GPI) of IgG and IgM isotypes. Extra-criteria aPL, especially IgA aB2GPI and IgG/IgM anti-phosphatidylserine/prothrombin antibodies (aPS/PT), have been strongly associated with thrombosis. However, their role in the general population suffering from stroke is unknown. We aim (1) to evaluate the aPL prevalence in ischemic stroke patients, (2) to determine the role of aPL as a risk factor for stroke, and (3) to create an easy-to-use tool to stratify the risk of ischemic stroke occurrence considering the presence of aPL and other risk factors.Materials and Methods: A cohort of 245 consecutive ischemic stroke patients was evaluated in the first 24 h after the acute event for the presence of classic aPL, extra-criteria aPL (IgA aB2GPI, IgG, and IgM aPS/PT) and conventional cardiovascular risk factors. These patients were followed-up for 2-years. A group of 121 healthy volunteers of the same age range and representative of the general population was used as reference population. The study was approved by the Ethics Committee for Clinical Research (Reference numbers CEIC-14/354 and CEIC-18/182).Results: The overall aPL prevalence in stroke patients was 28% and IgA aB2GPI were the most prevalent (20%). In the multivariant analysis, the presence of IgA aB2GPI (OR 2.40, 95% CI: 1.03–5.53), dyslipidemia (OR 1.70, 95% CI: 1.01–2.84), arterial hypertension (OR 1.82, 95% CI: 1.03–3.22), atrial fibrillation (OR 4.31, 95% CI: 1.90–9.78), and active smoking (OR 3.47, 95% CI: 1.72–6.99) were identified as independent risk factors for ischemic stroke. A risk stratification tool for stroke was created based on these factors (AUC: 0.75).Conclusions: IgA aB2GPI are an important independent risk factor for ischemic stroke. Evaluation of aPL (including extra-criteria) in cardiovascular risk factor assessment for stroke can potentially increase the identification of patients at risk of thrombotic event, facilitating a decision on preventive treatments.

show abstract

Apport de la détection des anticorps antiphosphatidylsérine/prothrombine (aPS/PT) dans le diagnostic et la prise en charge du syndrome des antiphospholipides (SAPL)

Delarue¹,

Dragon-Durey²,

Darnige³

2022

La Revue de Médecine Interne

View full text Add to dashboard Cite

Syndrome des antiphospholipides « séronégatif » : mythe ou réalité ?

Cited by 4 publications

References 136 publications

Current Promising Biomarkers and Methods in the Diagnostics of Antiphospholipid Syndrome: A Review

Current Promising Biomarkers and Methods in the Diagnostics of Antiphospholipid Syndrome: A Review

Presence of Extra-Criteria Antiphospholipid Antibodies Is an Independent Risk Factor for Ischemic Stroke

Apport de la détection des anticorps antiphosphatidylsérine/prothrombine (aPS/PT) dans le diagnostic et la prise en charge du syndrome des antiphospholipides (SAPL)

Contact Info

Product

Resources

About